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Screening and human papillomavirus (HPV) vaccine are the
most critical strategies for cervical cancer control.1 The
impact of vaccine programs has not been fully demonstrated
yet due to the long natural history of the neoplasia. Regions
that have implemented organized screening had efficiently
reduced their incidence and mortality rates. Even in Brazil,
where screening is opportunist, the cervical cancer rate is
going down, dropping to the fourth most common female
cancer.2–4
The acquired knowledge about the pathogenesis of cervical
cancer has proved that HPV DNA test is more efficient than
cytology in detecting precursor lesions and reducing the
incidence of cervical cancer. In screening programs, the HPV
DNA test anticipates the diagnosis with a higher sensitivity.5,6
The most robust evidence comes from the systematic review
by Ronco et al,6 who analyzed four randomized trials that
enrolled 176,464 women aged 20–64 years, who were ran-
domly assigned to the HPV DNA intervention group or the
cytology control group. The authors showed a benefit with the
HPV DNA test for the detection of invasive squamous cell
carcinoma (0.78, 0.49–1.25) that was even higher for adeno-
carcinoma (odds ratio [OR]: 0.31; 95%confidence interval [95%
CI]: 0.14–0.69).6
This finding might be related to the limitations of cytology
in detecting endocervical lesions: endocervical glands are
harder to sample and, given the rarity of these lesions, reading
and interpreting abnormal findings is more difficult.7–9
Although invasive adenocarcinomas are usually detected in
more advanced stages, cytology screening is associated with
the downstaging of these lesions.9
However, as cervical cancer rates are expected to fall, a
new debate emerges regarding cancers not related to HPV
infection, like some rare endocervical adenocarcinomas.
Invasive endocervical adenocarcinoma is a difficult histo-
logical type for pathologists. Recently, attempts are being
made to switch to a different endocervical adenocarcinoma
classification that would more precisely reflect the different
prognosis observed in the various subtypes.10,11 Currently,
misclassification is common. One of the proposals is the
classification based on the morphologic features linked to
HPV: HPV-associated (HPVA) and HPV-unassociated (NHPVA)
features. The NHPVA includes such subtypes as endometrioid,
gastric, minimal deviation, clear cell, serous andmesonephric
tumors, and is related to a worse prognosis than that of the
HPVA subtypes.11
The pathogenesis of NHPVA subtypes is poorly understood.
The minimal deviation and gastric subtypes may share the
same precursor lesion, which is called lobular endocervical
glandular hyperplasia, and some are associated with Peutz-
Jeghers syndrome.12,13 Serous tumors are associatedwith p53
gene mutations, as serous endometrial adenocarcinoma and
endometrioid tumorsmight represent endometrial cancers in
origin that have spread to the cervix.14
The positivity of HPV in adenocarcinomas is high, usually
around 90%. A recent study by Pirog et al15 has provided
comprehensive data on the genotype distribution of 760
adenocarcinomas cases from 38 countries between 1940
and 2009. The overall HPV prevalence was of 62.8%, raising
the concern about the possibility of missing almost 1/3 of
adenocarcinomas with HPV DNA test screening. Although
those cases were reviewed through three-level pathology,
the authors considered two main reasons for this low HPV
prevalence: aging of the paraffin-embedded tissues (older
samples showed lower positivity than recent ones), anddiffer-
ences in regional tissue-fixation protocols within countries.
Another relevant result was that HPV-negative samples were
more common in older women. It is not clear if HPV could be
lost during a slow progression tumor or if it is a non-HPV
pathogenesis.
Irrespective of the differences in prevalence rates, HPV
detection is harder to be demonstrated due to the relative
low viral load in the glandular epithelium. The thin epithelium
does not support a productive infection, as it is observed in the
squamous epithelium. TheHPV life cycle involves the infection
of a dividing cell and a reservoir in the basal layer. The ability
to drive cancer progression is related to the expression of
different proteins that may vary according to the position or
level of maturity of the cells. The less dynamic scenario of the
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glandular epithelium and the low number of integrated virus
copiesobserved inglandular lesionsarebarriers tounderstand
how these precursor lesions develop.15–17
Brazil and other Latin-American countries have demon-
strated some effect of the cytology opportunist screening in
reducing the incidence of cervical cancer in the last few
decades.4 However, this effect is much more discreet than
the one observed in countries that have implemented orga-
nized screening, with a high-complexity quality control pro-
gram and a population-based strategy of invitation (call and
recall system).18–20 For those countries, the shift to the HPV
DNA test will improve the efficiency of the programs, but the
impact of the superiorityof theHPVDNAtestmaynot result in
a significant reduction in rates since theyalready have reached
low incidence rates. For those countries, the question of the
‘missing adenocarcinomas’ seems to be more relevant, as it
may correspond to around 3% to 4% of the total of cervical
cancers, as claimed by Pirog et al.15 Even if this estimation is
correct, it should be considered that these rare cancers are
challenging to be found through cytology or HPV DNA tests.
In regions with moderate to high incidence of cervical
cancer, as in Brazil, this shift to the HPVDNA test may cause a
more pronounced impact on decreasing rates, particularly if
accompanied by an effort to implement organized screening
programs. The question of how to prevent and diagnose rare
adenocarcinoma subtypes (or the ‘missing adenocarcino-
mas’) is currently not as relevant as the necessity to reduce
the incidence of squamous cell cancer, irrespective of the test
used. Only in the near future, as the incidence of cervical
cancer drops, could the ‘missing adenocarcinomas’ emerge
as a critical problem in the screening program in Brazil.
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